Scholarlink

Background <p>We investigated the utility of <sup>18</sup>F-labeled prostate-specific membrane antigen positron emission tomography/computed tomography ([<sup>18</sup>F]PSMA-1007 PET/CT) for assessing residual tumor burden after neoadjuvant androgen deprivation therapy (nADT), compared with multiparametric magnetic resonance imaging (mpMRI).</p> Methods <p>This retrospective study included 20 patients with prostate cancer treated with nADT followed by radical prostatectomy. All patients underwent baseline mpMRI, post-nADT mpMRI, and [<sup>18</sup>F]PSMA-1007 PET/CT. Lesion-based diagnostic performance of [<sup>18</sup>F]PSMA-1007 PET/CT and mpMRI was compared using generalized estimating equations. Apparent diffusion coefficient (ADC) and transfer constant (Ktrans) values were compared between baseline and post-nADT using Wilcoxon signed-rank tests and between tumor and benign prostatic hyperplasia (BPH) using Mann–Whitney U tests.</p> Results <p>Baseline mpMRI identified 23 biopsy-confirmed lesions, and post-nADT, 21 showed residual tumor on pathology. [<sup>18</sup>F]PSMA-1007 PET/CT demonstrated significantly higher sensitivity (90.5% vs. 23.8%, <i>p</i> &lt; 0.001) and accuracy (87.0% vs. 26.1%, <i>p</i> &lt; 0.001) than mpMRI. Median ADC increased significantly after nADT (0.849 to 1.174 × 10<sup>− 3</sup> mm<sup>2</sup>/s, <i>p</i> = 0.005), while median Ktrans decreased (0.277 to 0.080&#xa0;min<sup>− 1</sup>, <i>p</i> = 0.005). Baseline ADC and Ktrans differed significantly between tumor and BPH (<i>p</i> = 0.001 and <i>p</i> = 0.012, respectively), but no significant post-nADT differences were observed (<i>p</i> = 0.831 and <i>p</i> = 0.701, respectively). Post-nADT SUVmax also did not differ between tumor and BPH (<i>p</i> = 0.639).</p> Conclusions <p><b>[</b><sup>18</sup>F]PSMA-1007 PET showed higher sensitivity and accuracy than mpMRI in detecting residual tumor after short-term nADT and may be useful for further management planning. These preliminary findings support the feasibility of [<sup>18</sup>F]PSMA-1007 PET for post-treatment assessment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The feasibility of [18F]PSMA-1007 PET/CT for response assessment in prostate cancer following neoadjuvant androgen deprivation therapy compared with mpMRI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Sangwoo Cho,
  • Hyo Jung Seo,
  • Hyunkyung Han,
  • Sangwon Lee,
  • Tae Joo Jeon,
  • Young Taik Oh,
  • Minsun Jung,
  • Mijin Yun

摘要

Background

We investigated the utility of 18F-labeled prostate-specific membrane antigen positron emission tomography/computed tomography ([18F]PSMA-1007 PET/CT) for assessing residual tumor burden after neoadjuvant androgen deprivation therapy (nADT), compared with multiparametric magnetic resonance imaging (mpMRI).

Methods

This retrospective study included 20 patients with prostate cancer treated with nADT followed by radical prostatectomy. All patients underwent baseline mpMRI, post-nADT mpMRI, and [18F]PSMA-1007 PET/CT. Lesion-based diagnostic performance of [18F]PSMA-1007 PET/CT and mpMRI was compared using generalized estimating equations. Apparent diffusion coefficient (ADC) and transfer constant (Ktrans) values were compared between baseline and post-nADT using Wilcoxon signed-rank tests and between tumor and benign prostatic hyperplasia (BPH) using Mann–Whitney U tests.

Results

Baseline mpMRI identified 23 biopsy-confirmed lesions, and post-nADT, 21 showed residual tumor on pathology. [18F]PSMA-1007 PET/CT demonstrated significantly higher sensitivity (90.5% vs. 23.8%, p < 0.001) and accuracy (87.0% vs. 26.1%, p < 0.001) than mpMRI. Median ADC increased significantly after nADT (0.849 to 1.174 × 10− 3 mm2/s, p = 0.005), while median Ktrans decreased (0.277 to 0.080 min− 1, p = 0.005). Baseline ADC and Ktrans differed significantly between tumor and BPH (p = 0.001 and p = 0.012, respectively), but no significant post-nADT differences were observed (p = 0.831 and p = 0.701, respectively). Post-nADT SUVmax also did not differ between tumor and BPH (p = 0.639).

Conclusions

[18F]PSMA-1007 PET showed higher sensitivity and accuracy than mpMRI in detecting residual tumor after short-term nADT and may be useful for further management planning. These preliminary findings support the feasibility of [18F]PSMA-1007 PET for post-treatment assessment.